$2.91 Billion is the total value of Camber Capital Management LP's 32 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 75.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SPY | New | SPDR S&P 500 ETF TRput | $396,330,000 | – | 1,000,000 | +100.0% | 13.60% | – |
| CHNG | Sell | CHANGE HEALTHCARE INC | $248,625,000 | +2.5% | 11,250,000 | -13.5% | 8.53% | +0.3% |
| WBA | Buy | WALGREENS BOOTS ALLIANCE INC | $205,875,000 | +72.1% | 3,750,000 | +25.0% | 7.06% | +68.3% |
| UHS | UNIVERSAL HLTH SVCS INCcl b | $186,746,000 | -3.0% | 1,400,000 | 0.0% | 6.41% | -5.2% | |
| VTRS | VIATRIS INC | $167,640,000 | -25.5% | 12,000,000 | 0.0% | 5.75% | -27.1% | |
| THC | TENET HEALTHCARE CORP | $156,000,000 | +30.2% | 3,000,000 | 0.0% | 5.35% | +27.3% | |
| HCA | Sell | HCA HEALTHCARE INC | $145,964,000 | +4.4% | 775,000 | -8.8% | 5.01% | +2.1% |
| PRGO | Sell | PERRIGO CO PLC | $113,316,000 | -15.5% | 2,800,000 | -6.7% | 3.89% | -17.4% |
| ALKS | Sell | ALKERMES PLC | $104,608,000 | -22.3% | 5,600,000 | -17.0% | 3.59% | -24.0% |
| ZBH | New | ZIMMER BIOMET HOLDINGS INC | $100,050,000 | – | 625,000 | +100.0% | 3.43% | – |
| MYGN | Sell | MYRIAD GENETICS INC | $91,350,000 | -7.6% | 3,000,000 | -40.0% | 3.14% | -9.7% |
| GSK | Sell | GLAXOSMITHKLINE PLCsponsored adr | $89,225,000 | -30.7% | 2,500,000 | -28.6% | 3.06% | -32.3% |
| IRWD | IRONWOOD PHARMACEUTICALS INC | $83,850,000 | -1.8% | 7,500,000 | 0.0% | 2.88% | -4.0% | |
| MRK | New | MERCK & CO. INC | $77,090,000 | – | 1,000,000 | +100.0% | 2.64% | – |
| BKD | Buy | BROOKDALE SR LIVING INC | $75,625,000 | +39.9% | 12,500,000 | +2.5% | 2.60% | +36.8% |
| GILD | New | GILEAD SCIENCES INC | $64,630,000 | – | 1,000,000 | +100.0% | 2.22% | – |
| TEVA | Buy | TEVA PHARMACEUTICAL INDS LTDsponsored ads | $63,470,000 | +46.2% | 5,500,000 | +22.2% | 2.18% | +42.9% |
| WELL | New | WELLTOWER INC | $58,020,000 | – | 810,000 | +100.0% | 1.99% | – |
| VTR | New | VENTAS INC | $48,006,000 | – | 900,000 | +100.0% | 1.65% | – |
| COLL | COLLEGIUM PHARMACEUTICAL INC | $47,400,000 | +18.3% | 2,000,000 | 0.0% | 1.63% | +15.7% | |
| IONS | New | IONIS PHARMACEUTICALS INC | $44,960,000 | – | 1,000,000 | +100.0% | 1.54% | – |
| OSUR | Buy | ORASURE TECHNOLOGIES INC | $41,720,000 | +21.3% | 3,575,000 | +10.0% | 1.43% | +18.6% |
| INCY | New | INCYTE CORP | $40,635,000 | – | 500,000 | +100.0% | 1.39% | – |
| NKTR | Sell | NEKTAR THERAPEUTICS | $40,000,000 | -5.9% | 2,000,000 | -20.0% | 1.37% | -8.0% |
| RETA | New | REATA PHARMACEUTICALS INCcl a | $39,880,000 | – | 400,000 | +100.0% | 1.37% | – |
| AVRO | AVROBIO INC | $39,762,000 | -9.0% | 3,133,333 | 0.0% | 1.36% | -11.0% | |
| RDUS | Sell | RADIUS HEALTH INC | $31,290,000 | -15.6% | 1,500,000 | -27.7% | 1.07% | -17.4% |
| BLUE | Buy | BLUEBIRD BIO INC | $30,150,000 | -12.9% | 1,000,000 | +25.0% | 1.04% | -14.8% |
| PBYI | PUMA BIOTECHNOLOGY INC | $24,835,000 | -5.3% | 2,555,000 | 0.0% | 0.85% | -7.4% | |
| MRTX | New | MIRATI THERAPEUTICS INC | $21,413,000 | – | 125,000 | +100.0% | 0.74% | – |
| TBIO | New | TRANSLATE BIO INC | $18,964,000 | – | 1,150,000 | +100.0% | 0.65% | – |
| INNV | New | INNOVAGE HLDG CORP | $16,764,000 | – | 650,000 | +100.0% | 0.58% | – |
| GLYC | Exit | GLYCOMIMETICS INC | $0 | – | -2,200,000 | -100.0% | -0.29% | – |
| ANGO | Exit | ANGIODYNAMICS INC | $0 | – | -540,362 | -100.0% | -0.29% | – |
| DRNA | Exit | DICERNA PHARMACEUTICALS INC | $0 | – | -525,000 | -100.0% | -0.41% | – |
| CHRS | Exit | COHERUS BIOSCIENCES INC | $0 | – | -2,200,000 | -100.0% | -1.34% | – |
| WBA | Exit | WALGREENS BOOTS ALLIANCE INCcall | $0 | – | -1,000,000 | -100.0% | -1.40% | – |
| BIIB | Exit | BIOGEN INC | $0 | – | -200,000 | -100.0% | -1.72% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -400,000 | -100.0% | -2.39% | – |
| BHC | Exit | BAUSCH HEALTH COS INC | $0 | – | -4,250,000 | -100.0% | -3.10% | – |
| ABBV | Exit | ABBVIE INCcall | $0 | – | -1,000,000 | -100.0% | -3.76% | – |
| BMY | Exit | BRISTOL-MYERS SQUIBB COcall | $0 | – | -2,000,000 | -100.0% | -4.35% | – |
| GILD | Exit | GILEAD SCIENCES INCcall | $0 | – | -2,500,000 | -100.0% | -5.11% | – |
| ALXN | Exit | ALEXION PHARMACEUTICALS INC | $0 | – | -1,175,000 | -100.0% | -6.44% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.